Inactive Instrument

Trillium Therapeutics

TRIL

CA89620X5064

Trillium Appoints Dr. Henry Friesen as Director Emeritus and Retirement from the Board of Directors

June 05, 2018 at 07:01 am

Trillium announced the appointment of Dr. Henry Friesen as Director Emeritus. The company announced Dr. Friesen’s retirement from the Board of Directors.

Latest news about Trillium Therapeutics

TCR2 Therapeutics Appoints Chief Business and Strategy Officer	22-01-12	MT
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	21-12-13	DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover	21-12-13	MT
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index	21-11-19	CI
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition	21-11-17	MT
Trillium Therapeutics Inc. Announces Executive Changes	21-11-17	CI
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer	21-11-17	CI
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer	21-11-17	CI
Benchmark Downgrades Trillium Therapeutics to Hold From Buy	21-11-17	MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval	21-11-17	MT
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index	21-11-17	CI
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.	21-11-16	CI
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-11-05	DJ
Trillium Therapeutics Brief: Says Received Final Court Order Approving Arrangement With PF Argentum ULC, a wholly-owned, indirect subsidiary of Pfizer Inc	21-10-28	MT
Trillium Therapeutics Brief: Securityholders Approve Acquisition by Pfizer	21-10-26	MT
Transcript : Trillium Therapeutics Inc. - Shareholder/Analyst Call	21-10-26
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Composite Index	21-09-20	CI
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Completion Index	21-09-20	CI
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Capped Composite Index	21-09-20	CI
Health Care Up Amid Deal Activity -- Health Care Roundup	21-08-30	DJ
TRILLIUM THERAPEUTICS : Benchmark Adjusts Price Target for Trillium Therapeutics to C$23.34 From C$26.41, Maintains Buy Rating	21-08-24	MT
Trackinsight: Rising oil and gold prices propel Canadian shares	21-08-24	TI
Today on Wall Street: A new central bank theory	21-08-24
TRILLIUM THERAPEUTICS : Craig-Hallum Downgrades Trillium Therapeutics to Hold From Buy	21-08-24	MT

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don?t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium's second SIRP?Fc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRP? as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Sector

More about the company

Trillium Therapeutics

Equities

TRIL

CA89620X5064

Trillium Appoints Dr. Henry Friesen as Director Emeritus and Retirement from the Board of Directors

Latest news about Trillium Therapeutics

Chart Trillium Therapeutics

Company Profile